Animal coagulation function activity testing evaluates the hemostatic capacity of blood specimens from companion animals, livestock, laboratory species, and exotic animals through validated assays including prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen, individual clotting factor activities, and platelet function. Accredited third-party laboratories perform these analyses to support veterinary clinical diagnosis, preclinical safety studies, medical device hemocompatibility evaluation under ISO 10993-4, and antithrombotic drug development. Accurate, species-specific coagulation data are essential for identifying bleeding disorders, detecting hypercoagulable states, and monitoring therapeutic interventions in animal populations.
Technical Overview
Animal coagulation function activity testing is a laboratory discipline that quantifies the functional integrity of the hemostatic system in blood collected from animals. Hemostasis comprises primary hemostasis (vascular response and platelet plug formation), secondary hemostasis (the soluble coagulation cascade), and fibrinolysis (clot breakdown). Functional assays measure how effectively each of these components operates, rather than merely measuring antigen concentration, because an abnormal quantity of a factor does not always correspond to abnormal biological activity.
The coagulation cascade is conventionally divided into the extrinsic pathway (tissue factor and factor VII), the intrinsic pathway (factors XII, XI, IX, and VIII), and the common pathway (factors X and V, prothrombin, and fibrinogen), culminating in thrombin generation, fibrin formation, and factor XIII-mediated cross-linking. Global screening tests map onto this architecture: prothrombin time evaluates the extrinsic and common pathways, activated partial thromboplastin time evaluates the intrinsic and common pathways, and thrombin time with fibrinogen assays examines the final conversion steps. Fibrin degradation products and D-dimer reflect fibrinolytic turnover, while viscoelastic methods integrate cellular and plasma components into a global profile.
Meaningful interpretation requires species-specific validation. Clotting times, factor activities, platelet reactivity, and fibrinolytic potential vary substantially among dogs, cats, horses, ruminants, rabbits, and rodents. For example, horses frequently exhibit shorter clotting times and a physiologic tendency toward hypercoagulability, cats show distinctive platelet responses to agonists, and rodents require micro-volume adaptations due to limited collectable blood volumes. Professional laboratories therefore establish species- and instrument-specific reference intervals and verify reagent cross-reactivity before reporting results.
Animal coagulation testing supports several regulatory and clinical frameworks. Medical device hemocompatibility evaluation is guided by ISO 10993-4 (adopted in China as GB/T 16886.4), which assigns coagulation, platelet, hematology, thrombosis, and complement test categories. Laboratory competence is demonstrated under ISO/IEC 17025 quality management systems, preclinical studies intended for regulatory submission are conducted under Good Laboratory Practice principles, and material-level blood-contact assessment is further addressed by standards such as ASTM F756.
Testing Samples
Citrated Plasma
The primary specimen for coagulation activity testing is whole blood collected into 3.2% trisodium citrate anticoagulant at a strict 9:1 blood-to-anticoagulant ratio. The sample is centrifuged to produce platelet-poor plasma, which is used for prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, factor activity, inhibitor, and fibrinolytic marker assays. Heparinized or EDTA tubes are not acceptable for functional coagulation testing, and under-filled citrate tubes alter the anticoagulant ratio and invalidate clotting time results.
Whole Blood
Native citrated whole blood is required for activated clotting time, viscoelastic hemostatic testing, and impedance-based platelet aggregation. These whole-blood methods preserve leukocyte and erythrocyte contributions to coagulation and are typically performed within two to four hours of collection.
Platelet-Rich Plasma
Platelet-rich plasma, prepared by gentle centrifugation, is used for light transmittance aggregometry with agonists such as ADP, collagen, arachidonic acid, and ristocetin. The platelet count within the prepared plasma is normalized before analysis to ensure comparability between samples.
Covered Species and Specimen Volumes
- Companion animals: canine, feline, and exotic pets
- Equine species: horses and donkeys
- Livestock: cattle, pigs, sheep, and goats
- Laboratory animals: rabbits, rats, mice, guinea pigs, hamsters, and miniature pigs
- Special categories: avian, reptilian, and aquatic species for research programs, with adapted collection and assay protocols
Sample Handling and Stability
- Clean venipuncture with minimal tissue trauma and prompt, gentle tube inversion
- Double centrifugation to achieve platelet-poor plasma for factor and inhibitor assays
- Short-term storage at 2 to 8 degrees Celsius with testing of screening panels generally within 24 hours
- Long-term storage at minus 20 or minus 70 degrees Celsius for factor activities, avoiding repeated freeze-thaw cycles
- Cold-chain transport with temperature monitoring for shipped specimens
Testing Items
Testing portfolios are structured in tiers, progressing from global screening to individual component quantification:
- Global screening tests: prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen by the Clauss method, and activated clotting time
- Individual coagulation factor activities: factors II, V, VII, VIII, IX, X, XI, and XII by one-stage assays using factor-deficient substrate plasmas; factor XIII screening by clot solubility or activity assay
- Physiologic inhibitors: antithrombin III activity, protein C activity, and protein S activity
- Fibrinolytic markers: D-dimer, fibrin and fibrinogen degradation products, plasminogen activity, and euglobulin lysis time
- Platelet function: platelet count, aggregation response to ADP, collagen, arachidonic acid, and ristocetin; closure-time testing; platelet activation markers by flow cytometry
- Von Willebrand factor: antigen concentration and ristocetin cofactor activity
- Global viscoelastic parameters: reaction time, clot kinetics, alpha angle, maximum amplitude, and lysis indices from thromboelastography-type tracings
- Therapeutic monitoring: anti-factor Xa activity for unfractionated and low-molecular-weight heparin
Testing Methods
One-Stage Clotting Assays
Clot formation is detected by optical, mechanical, or magnetic sensing after recalcification with species-appropriate activators. Prothrombin time uses thromboplastin reagents with defined sensitivity indices, while activated partial thromboplastin time uses contact activators such as silica or ellagic acid. Factor activity is quantified by mixing dilutions of patient plasma with specific factor-deficient substrate plasma and comparing clotting times against calibration curves, with results expressed as a percentage of pooled species reference plasma activity.
Chromogenic Substrate Assays
Synthetic peptide substrates release a chromophore upon cleavage by the target enzyme, and absorbance measured near 405 nanometers is proportional to enzymatic activity. Chromogenic methods are preferred for antithrombin, protein C, anti-factor Xa, plasminogen, and alternative factor VIII and IX assays because they offer high specificity and reduced interference from nonspecific inhibitors or lupus-type anticoagulants.
Immunological Assays
Latex-enhanced immunoturbidimetry and enzyme-linked immunosorbent assays quantify D-dimer, fibrin degradation products, and von Willebrand factor antigen. Antibody cross-reactivity must be verified for each target species before veterinary application, because epitope conservation between species varies considerably.
Viscoelastic Hemostatic Testing
Thromboelastography-type analysis records the evolving shear elasticity of a clotting whole-blood sample, generating parameters that describe clot initiation speed, clot kinetics, clot strength, and fibrinolysis. This global method is particularly valuable for detecting hypercoagulability in canine immune-mediated hemolytic anemia, parvoviral enteritis, and equine colic or laminitis, and for guiding transfusion decisions.
Platelet Function Testing
Light transmittance aggregometry, whole-blood impedance aggregometry, closure-time systems, and flow-cytometric activation markers are applied according to the clinical or research objective. Agonist panels are species-optimized because platelet receptor expression and response magnitudes differ markedly among animals.
Method Validation and Quality Control
Validated methods demonstrate intra-assay and inter-assay precision, accuracy against reference materials or comparative methods, linearity, and dilution recovery. Species-specific reference intervals are established from statistically adequate populations of healthy animals, and control materials at multiple levels are included in every analytical run. Pipette calibration, temperature control, reagent lot qualification, and participation in interlaboratory comparison programs sustain compliance with ISO/IEC 17025 requirements.
Applications
Veterinary Clinical Diagnosis
Coagulation panels localize bleeding diatheses to primary or secondary hemostasis, diagnose disseminated intravascular coagulation, document vitamin K antagonist rodenticide toxicosis, screen inherited disorders such as hemophilia A and B and von Willebrand disease, and provide pre-operative hemostatic assessment for surgical candidates.
Preclinical Safety Assessment
Coagulation endpoints are incorporated into Good Laboratory Practice toxicology studies to detect compound-induced coagulopathy, interpret findings in parallel with hepatic and hematologic data, and define no-observed-adverse-effect levels for blood-related parameters.
Medical Device Hemocompatibility
Under ISO 10993-4 and its European and Chinese adoptions, blood-contacting devices are evaluated for effects on coagulation, platelets, and thrombus formation using static extraction and dynamic flow-loop models with animal blood, supplemented by in vivo shunt studies in appropriate species.
Pharmaceutical and Biological Product Development
Efficacy studies of antithrombotic, procoagulant, and hemostatic agents rely on activity testing in animal models such as ferric chloride vascular injury, venous stasis, and arteriovenous shunt thrombosis, with ex vivo coagulation assays providing quantitative pharmacodynamic readouts.
Research and Animal Model Characterization
Genetically modified rodents, large-animal thrombosis models, and comparative hemostasis research all depend on validated activity assays to characterize phenotypes and quantify treatment effects across study groups.
Livestock and Equine Health Monitoring
Herd-level and individual monitoring of sepsis-associated coagulopathy, transition-period metabolic stress, and surgery-related thrombotic risk supports preventive veterinary programs in production animals and sport horses.
FAQ
Which anticoagulant must be used for functional coagulation testing?
Sodium citrate at a 3.2% concentration with a 9:1 blood-to-anticoagulant ratio is the standard. EDTA chelates calcium irreversibly and heparin directly inhibits thrombin, so neither is suitable for activity assays.
Why cannot human reference intervals be applied to animals?
Clotting times, factor activities, platelet reactivity, and fibrinolytic activity differ substantially across species. Applying human intervals produces misclassification, so laboratories must establish and apply species-specific reference ranges validated on the analytical platform in use.
Which test is most sensitive for anticoagulant rodenticide toxicosis?
Prothrombin time is typically the earliest abnormality because factor VII has the shortest half-life; activated partial thromboplastin time prolongs as other factors decline. Confirmation includes factor activity analysis, clinical history, and response to vitamin K1 therapy.
What sample volumes are needed, particularly for rodents?
Canine and feline panels usually require 1.8 to 2.7 milliliters of citrated blood. For mice and rats, micro-methods and diluted assay formats allow panels from approximately 0.5 to 1.0 milliliter, with sampling strategies determined by the study design.
How should samples be stored and shipped?
Plasma for screening tests is generally analyzed within 24 hours at 2 to 8 degrees Celsius. Factor activities, inhibitors, and fibrinolytic markers should be frozen at minus 70 degrees Celsius and shipped on dry ice with documented cold-chain integrity.
How is heparin therapy monitored in animals?
The anti-factor Xa chromogenic assay is the preferred monitoring tool in dogs and cats because the sensitivity of activated partial thromboplastin time reagents to heparin varies widely between species and analytical platforms.
How are results reported?
Clotting times are reported in seconds with the applicable species-specific reference interval, factor activities as a percentage of pooled reference plasma, and viscoelastic parameters with interpretive classification of hypo-, normo-, or hypercoagulable status, accompanied by method and reagent documentation for traceability.
